Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy-Reference-Cited by-同舟云学术

Systemic Therapy for the Treatment of Hormone-Sensitive Metastatic Prostate Cancer: from Intermittent Androgen Deprivation Therapy to Chemotherapy

Published:2015-02-13 Issue:3 Volume:16 Page:
ISSN:1527-2737
Container-title:Current Urology Reports
language:en
Short-container-title:Curr Urol Rep

Author:

Liaw Bobby C.,Shevach Jeffrey,Oh William K.

Publisher

Springer Science and Business Media LLC

Subject

Urology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11934-015-0486-x.pdf

Reference68 articles.

1. Huggins C, Hodges CV. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–7.

2. Huggins C, Stevens RE, Hodgkins CV. The effects of castration on advanced carcinoma of the prostate. Arch Surg. 1941;43(2):209–23.

3. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605.

4. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.

5. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24(24):3984–90.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The circHMGCS1-miR-205–5p-ErBB3 axis mediated the Sanggenon C-induced anti-proliferation effects on human prostate cancer;Pharmacological Research;2023-01

2. Expanding the use of abiraterone in prostate cancer: Is earlier always better?;Cancer Biology & Therapy;2017-12-08

3. RETRACTED: Low density lipoprotein receptor targeted doxorubicin/DNA-Gold Nanorods as a chemo- and thermo-dual therapy for prostate cancer;International Journal of Pharmaceutics;2016-11

4. A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”;Üroonkoloji Bülteni;2016-06-16

5. Újdonságok a prosztatarák diagnosztikájában és kezelésében;Orvosi Hetilap;2016-03